Below is a letter signed jointly by DEA Administrator Anne Milgram, HHS Assistant Secretary for Health Rachel L. Levine, MD, and HHS Assistant Secretary for Mental Health and Substance Use Miriam Delphin-Rittmon, PhD, supporting the expansion of medications for opioid use disorder (MOUD) especially in rural or underserved areas. DEA supports collaboration amongst all DEA registrants to ensure there is an adequate and uninterrupted supply of MOUD products when appropriately prescribed. Distributors should carefully examine any quantitative thresholds they have established to ensure that individuals with opioid use disorder (OUD) who need buprenorphine are able to access it without undue delay.
For more information, visit www.samhsa.gov and/or www.deadiversion.usdoj.gov.
